Clinical trial
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe…
NCT00102921 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00102921 |
|---|---|
| Title | Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease |
| Official title | Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn's Disease |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | CCX282-B |
| Enrollment | 70 |
| Start date | Aug 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Feb 7, 2005 |
| Last update posted | Mar 6, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: